AstraZeneca's Oral GLP-1 Elecoglipron Officially Enters Phase 3 Clinical Trials
Miles Bennett
AstraZeneca is pushing its oral weight-loss drug elecoglipron into Phase 3 trials after positive mid-stage results — 10.5% weight loss at 26 weeks. That trails Novo Nordisk and Lilly, but a side-effect dropout rate of just ~5% signals a different bet: not 'who loses the most weight,' but 'who can actually stay on the pill.'
What did the Phase 2 trials actually show?
In the VISTA trial (obesity indication), patients on elecoglipron lost an average of 10.5% body weight at 26 weeks and 11.8% at 36 weeks.
In the SOLSTICE trial (type 2 diabetes indication), HbA1c — a blood marker reflecting average blood sugar over the past 2–3 months — dropped 1.9% from baseline.
AstraZeneca says the safety profile is consistent with other GLP-1 receptor agonists — a class of drugs that mimic a gut hormone to create a feeling of fullness, driving weight loss and blood-sugar control. No unexpected new risk signals.
How does it stack up against Novo and Lilly?
Novo Nordisk's oral Wegovy delivered roughly 17% weight loss at 64 weeks. Lilly's Foundayo posted 12.4% in mid-stage data.
Elecoglipron's 11.8% at 36 weeks is, on raw numbers, behind both. This means → if the race is purely "who sheds the most weight," elecoglipron is not winning right now.
In plain terms = the gold and silver medals are already spoken for. AstraZeneca is not here to take the crown — it is trying to compete on a different dimension entirely.
Why is "low dropout rate" its core selling point?
Elecoglipron's side-effect-related dropout rate was roughly 5%. Lilly's Foundayo hit as high as 17% in mid-stage trials.
This means → most patients on elecoglipron actually finished the course, instead of quitting because of nausea or vomiting.
In plain terms = a weight-loss drug that many people can't tolerate has inflated paper results. AstraZeneca is betting that retention — keeping patients on therapy — matters as much as peak efficacy.
R&D chief Sharon Barr: "Our dropout rates are extremely low, and that really speaks to the effectiveness and durability of this therapy."
What is the "combination therapy" play?
AstraZeneca has folded elecoglipron into study plans alongside heart-failure and kidney drug Farxiga, an experimental cholesterol-lowering agent, and approved hypertension drug Baxfendy.
CFO Aradhana Sarin: "Where our strategy is truly differentiated is in combination therapy."
This means → AstraZeneca does not want to sell a single weight-loss pill. It wants to sell a metabolic-disease bundle — packaging its existing cardiovascular and kidney drugs into a product matrix that Lilly and Novo cannot easily replicate in the near term.
What will Phase 3 test, and when could this reach the market?
Phase 3 will evaluate elecoglipron in obese patients with and without type 2 diabetes, covering both monotherapy and combination regimens.
AstraZeneca expects the drug could launch no earlier than after 2027.
In plain terms = even if everything goes right, the pill is at least two years away from pharmacy shelves. Phase 3 results will determine whether the "low dropout + combo therapy" narrative can graduate from concept to hard data.
Content is for reference only, not financial advice.